The increased use of tumor profiling and the introduction of alternative treatment regimens for HER2-positive patients, along with updated UK guidelines favoring lower-dose anthracycline regimens, reduced the number of eligible breast cancer patients.27 The gene discussed is ERBB2; the disease is breast carcinoma.